Does supplementation of extra Magnesium daily to first time pregnant healthy women prevent blood pressure increase during pregnancy?

Magnesium supplementation and blood pressure in pregnancy - a double-blind randomized multicenter study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN13890849

Enrollment

200

Registered

2018-04-27

Start date

2014-08-15

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood pressure in pregnancy Pregnancy and Childbirth Blood pressure in pregnancy

Interventions

After oral and written consent, participants are randomised in a computerised double-blind procedure to receive either Mg (400 mg Magnesium Extra, Diasporal®) or placebo, taken daily. The code is not

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Nulliparity 2. No regular medication 3. Normotension 4. Singleton pregnancy 5. Maternity age >18 years and < 40 years

Exclusion criteria

Exclusion criteria: 1. Age 40 years 2. Multiple pregnancy 3. Trombophilia 4. Previous labour 5. Diabetes 6. Chronic HT 7. Kidney disease 8. Heart disease 9. Regular medication 10. History of cardiac arrhythmia 11. Heredity of sudden cardiac arrest

Design outcomes

Primary

Measure	Time frame
Blood pressure is measured using manual sphygmomanometer at 2-3 week intervals throughout the pregnancy, and obtained from medical records at labour.	—

Secondary

Measure	Time frame
1. Biomarkers for hypertensive disorders ( IL-6, CRP, urate, cystatin C, Mg, Ca, albumin, creatinine and glomerular filtration rate (GFR) are analysed from blood samples at gestational weeks 12-14 and 35. 2. Labour and foetal outcomes (gestational length at birth, excessive bleeding >1000 ml, instrumental delivery, duration of active labour, Apgar score at five minutes, pH in the arterial umbilical cord, birth weight and need of care at a neonatal intensive care unit) are collected from medical records after delivery.	—

Measure

Time frame

1. Biomarkers for hypertensive disorders ( IL-6, CRP, urate, cystatin C, Mg, Ca, albumin, creatinine and glomerular filtration rate (GFR) are analysed from blood samples at gestational weeks 12-14 and 35. 2. Labour and foetal outcomes (gestational length at birth, excessive bleeding >1000 ml, instrumental delivery, duration of active labour, Apgar score at five minutes, pH in the arterial umbilical cord, birth weight and need of care at a neonatal intensive care unit) are collected from medical records after delivery.

—

Countries

Sweden

Contacts

Public ContactMaria Bullarbo

maria.bullarbo@vgregion.se+46706257092

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026